OPRX OptimizeRx Corp Insider Trading

Director Lang James Paul buys 321,408 shares of OPRX at $7.60; holdings surge 472.4% to 389,452 shares.

Director Lang James Paul purchased 321,408 shares at $7.60 on 2025-03-14, increasing his stake from 68,044 to 389,452 shares—a 472.4% expansion of his prior holdings worth $2,443,761.45. This substantial open-market accumulation occurred near the low end of the 52-week range ($3.82–$13.17), at a 34.6% discount from the 52-week high. OptimizeRx is currently unprofitable with a negative $-9,124,000.00 net income on quarterly revenue of $21,309,000.00, though the company has achieved 14.5% annual revenue growth. The magnitude and concentration of this purchase—in a single transaction—is material and warrants analysis of the director's business outlook and capital allocation priorities given the company's present loss position.

OptimizeRx CEO William Febbo purchases 20,000 shares at $5.01 amid 67.1% decline from 52-week high; stock +39.1% in 30 days

CEO William Febbo acquired 20,000 shares (20.0K shares) at $5.01 on 2024-12-12, bringing his total holdings to 601,253 shares (601.3K shares) after a +3.4% increase in his position. The purchase occurs at a significant discount to the 52-week high of $16.17, with the stock currently trading at -67.1% from that peak, though it has recovered +39.1% over the past 30 days. OptimizeRx remains structurally unprofitable—reporting a net loss of $-9.1M in its latest quarter and negative full-year net income—though the company has posted annual revenue growth of +14.5% and generates $21.3M in quarterly revenue. The timing of this insider buy during a pronounced drawdown warrants monitoring for what it may signal about management's assessment of near-term prospects, particularly given the company's ongoing losses and the recent price rebound.